Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ompile is a branded generic medication developed by Janjaes Pharmaceutical, primarily indicated for the management of hemorrhoids. It is marketed in two distinct forms: Ompile Tablets, which contain a combination of the vasoprotective agent calcium dobesilate and a standardized extract of *Euphorbia prostrata* (referred to as Euphorbia Tri Extract), and Ompile Cream, which utilizes herbal ingredients for topical relief. Calcium dobesilate functions by reducing capillary permeability and fragility, improving venous tone, and inhibiting the synthesis of inflammatory mediators like prostaglandins. The *Euphorbia prostrata* extract provides complementary anti-inflammatory, analgesic, and hemostatic properties, helping to reduce bleeding, pain, and swelling associated with internal and external hemorrhoidal disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium dobesilate + euphorbia prostrata extract.